| ZFIN ID: ZDB-EXP-260930-8 |
Experiment Conditions Description: chemical treatment: ethanol, chemical treatment: CX-5461
| chemical treatment: ethanol |
|---|
| Name: | chemical treatment |
|---|---|
| Synonyms: | |
| Definition: | Experimental condition in which the fish is treated with a chemical substance. This treatment could be administered by adding the chemical substance to the tank water, injections, or by consumption. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000111] |
| Name: | ethanol |
|---|---|
| Synonyms: | 1-hydroxyethane, [CH2Me(OH)], [OEtH], Aethanol, Aethylalkohol, alcohol, alcohol etilico, alcool ethylique, Alkohol, C2H5OH, Dehydrated ethanol, etanol, ethanol, Ethyl alcohol, EtOH, hydroxyethane, Methylcarbinol, spiritus vini |
| Definition: | A primary alcohol that is ethane in which one of the hydrogens is substituted by a hydroxy group. |
| Ontology: | ChEBI [CHEBI:16236] ( EBI ) |
| chemical treatment: CX-5461 |
|---|
| Name: | chemical treatment |
|---|---|
| Synonyms: | |
| Definition: | Experimental condition in which the fish is treated with a chemical substance. This treatment could be administered by adding the chemical substance to the tank water, injections, or by consumption. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000111] |
| Name: | CX-5461 |
|---|---|
| Synonyms: | 2-(4-methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-5H-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-5H-benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, CX 5461, CX5461 |
| Definition: | An organic heterotetracyclic compound that is 5-oxo-5H-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxylic acid substituted by a 4-methyl-1,4-diazepan-1-yl group at position 2 and in which the carboxy group at position 6 is substituted by a [(5-methylpyrazin-2-yl)methyl]nitrilo group. An inhibitor of ribosomal RNA (rRNA) synthesis which specifically inhibits RNA polymerase I-driven transcription of rRNA in several cancer cell lines. It is currently in phase I/II clinical trials for advanced hematologic malignancies and triple-negative breast cancer with BRCA1/2 mutation. |
| Ontology: | ChEBI [CHEBI:156287] ( EBI ) |
| Publication: | Flentke et al., 2024 |
|---|